Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease
International Journal of Molecular Sciences · 28.11.2024 · 25 (23) · 12809
DOI: 10.3390/ijms252312809 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.11.2024. Verfasst von Diren Beyoğlu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Administrative Sciences, College of Pharmacy and Health Sciences, Western New England University, Springfield, MA 01…. Hauptthemen laut MEDLINE: Obesity, Metabolomics. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
From a detailed review of 90 experimental and clinical metabolomic investigations of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), we have developed metabolomic hallmarks for both obesity and MASLD. Obesity studies were conducted in mice, rats, and humans, with consensus biomarker groups in plasma/serum being essential and nonessential amino acids, energy metabolites, gut microbiota metabolites, acylcarnitines and lysophosphatidylcholines (LPC), which formed the basis of the six metabolomic hallmarks of obesity. Additionally, mice and rats shared elevated cholesterol, humans and rats shared elevated fatty acids, and humans and mice shared elevated VLDL/LDL, bile acids and phosphatidylcholines (PC). MASLD metabolomic studies had been performed in mice, rats, hamsters, cows, geese, blunt snout breams, zebrafish, and humans, with the biomarker groups in agreement between experimental and clinical investigations being energy metabolites, essential and nonessential amino acids, fatty acids, and bile acids, which lay the foundation of the five metabolomic hallmarks of MASLD. Furthermore, the experimental group had higher LPC/PC and cholesteryl esters, and the clinical group had elevated acylcarnitines, lysophosphatidylethanolamines/phosphatidylethanolamines (LPE/PE), triglycerides/diglycerides, and gut microbiota metabolites. These metabolomic hallmarks aid in the understanding of the metabolic role played by obesity in MASLD development, inform mechanistic studies into underlying disease pathogenesis, and are critical for new metabolite-inspired therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical and Administrative Sciences, College of Pharmacy and Health Sciences, Western New England University, Springfield, MA 01119, USA.
- Division of Gastroenterology, Hepatology and Nutrition, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
ORCID-Profile: Diren Beyoğlu, Yury V Popov, Jeffrey R Idle
Zitieren
APA
Beyoğlu, D., Popov, Y. V., & Idle, J. R. (2024). Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences, 25(23), 12809. https://doi.org/10.3390/ijms252312809
Vancouver
Beyoğlu D, Popov YV, Idle JR. Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease. International Journal of Molecular Sciences. 2024;25(23):12809. doi:10.3390/ijms252312809
BibTeX
@article{Beyolu2024,
author = {Beyoğlu, Diren and Popov, Yury V and Idle, Jeffrey R},
title = {Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {23},
pages = {12809},
doi = {10.3390/ijms252312809}
}
EUVIMED